STUDIO

SynAct

SynAct Pharma summarises busy second quarter

SynAct Pharma's CEO Jeppe Øvlesen and CFO Patrik Renblad visit BioStock's studio to talk about the second quarter report, the uplisting to Nasdaq Stockholm...

RECOMMENDED READING

Aptahem increasingly close to clinical studies

BioStock reached out to Malmö company Aptahem, which is developing an emergency treatment for...

BioStock Investor Meeting, September 14

On September 14, we will arrange the next BioStock Investor Meeting, where life science...

EVENT